for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Getinge AB

GETIb.ST

Latest Trade

166.90SEK

Change

-2.35(-1.39%)

Volume

108,059

Today's Range

166.75

 - 

169.00

52 Week Range

76.92

 - 

171.85

As of on the Stockholm Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
169.25
Open
168.85
Volume
108,059
3M AVG Volume
22.03
Today's High
169.00
Today's Low
166.75
52 Week High
171.85
52 Week Low
76.92
Shares Out (MIL)
272.37
Market Cap (MIL)
42,824.68
Forward P/E
26.28
Dividend (Yield %)
0.59

Next Event

Getinge AB at DNB Nordic-American Life Science Conference

Latest Developments

More

Getinge Q3 Adjusted EBITA Up At SEK 677 Million

Getinge Informs About A Global Class 1 Recall For Cardiosave IABP And CS100/300

Getinge April-June Adjusted EBITA Up At SEK 591 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Getinge AB

Getinge AB is a Sweden-based company active in the healthcare sector. It provides products and services for intensive care units, sterilization centers, elderly care and companies and institutions active in the life sciences area. Its operations are divided into three business areas: The Medical Systems business area offers equipment for surgical disciplines, cardiology and intensive care; the Extended Care business area offers products and services geared toward the hospital and elderly care markets, including solutions for preventing the risk of pressure ulcers and deep vein thrombosis, and the Infection Control business area features systems for preventing the occurrence and spread of infection. Its products comprise disinfectors, sterilizers, including low temperature sterilization solutions, information technology (IT) solutions, as well as advice, training and technical support. The Company's products are sold under the Getinge, Lancer, ArjoHuntleigh and MAQUET brands.

Industry

Medical Equipment & Supplies

Contact Info

Lindholmspiren 7

+46.3.5155500

http://www.getingegroup.com/

Executive Leadership

Johan Malmquist

Chairman of the Board

Mattias Perjos

President, Chief Executive Officer, Director

Carl Bennet

Vice Chairman of the Board

Johan Stern

Vice Chairman of the Board

Lars Sandstrom

Chief Financial Officer

Key Stats

3.27 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, SEK)

2016

29.8K

2017

22.5K

2018

24.2K

2019(E)

26.6K
EPS (SEK)

2016

10.448

2017

8.520

2018

5.910

2019(E)

6.411
Price To Earnings (TTM)
44.56
Price To Sales (TTM)
1.65
Price To Book (MRQ)
2.25
Price To Cash Flow (TTM)
14.08
Total Debt To Equity (MRQ)
57.04
LT Debt To Equity (MRQ)
57.04
Return on Investment (TTM)
2.79
Return on Equity (TTM)
2.38

Latest News

Latest News

BRIEF-Getinge Q3 Adjusted EBITA Up At SEK 677 Million

* Q3 NET SALES SEK 6,236 MILLION (REFINITIV POLL: SEK 6,074 MILLION)

UPDATE 1-Sweden's Getinge order book beat sends shares higher

Swedish medical technology group Getinge reported stronger than expected orders thanks to a robust performance in capital goods and in emerging markets, sending its stock up more than 10 percent on Tuesday.

Sweden's Getinge says costs could rise as Q2 earnings lag

Swedish medical technology group Getinge said that it might see higher operating expenses in future quarters, after second-quarter core earnings missed expectations as higher demand for certain products and in some markets inflated costs and hit margins.

Getinge to step up cost cuts after deeper-than-expected Q1 loss

Swedish medical technology group Getinge said on Thursday it would step up cost cuts after it reported a bigger than expected operating loss for the first quarter, sending its shares down nearly 5 percent.

BRIEF-Getinge Q1 operating result lags forecast

* Q1 OPERATING PROFIT (EBIT) AMOUNTED TO SEK -161 M (302), CURRENCY EFFECTS HAD A NEGATIVE IMPACT OF SEK -115 M ON EBIT

Getinge makes another provision for Brazil fraud probe

Swedish medical technology group Getinge said on Wednesday it would book a 350 million crown ($42.6 million) provision in the first quarter related mainly to a fraud probe in Brazil.

Getinge core profit lags forecast, sees slight growth in 2018

Swedish medical technology group Getinge on Monday reported a fourth-quarter core profit far below market forecasts and said it expected slight growth in organic sales this year.

BRIEF-Getinge Q4 core profit far below forecast​

* Q4 EBITA 1** AMOUNTED TO SEK 1,111 M (1,689) WITH AN EBITA 1 MARGIN OF 15.1% (22.7)

UPDATE 1-Getinge sets new financial targets ahead of Arjo listing

Swedish medical technology firm Getinge on Friday announced new financial targets following the proposed distribution and separate listing of its patient & post-acute care business, now called Arjo.

BRIEF-Getinge sets new financial targets after distribution of Arjo

* Revised strategy, new financial targets and restated financial information for Getinge (excluding Arjo)

REFILE-UPDATE 2-Getinge hopes to spin off PPAC division this year after Q3 profit dives

Medical technology firm Getinge reported on Wednesday quarterly core profits below expectations, sending its shares down, and said it now hoped to spin off and list its smallest division by year-end.

BRIEF-Getinge Q3 core profit lags expectations, targets PPAC listing by year-end ​

* Q3 order intake increased by 2.2% to sek 7,334 m (7,176). Order intake increased organically by 4.7%.

BRIEF-Getinge's rights issue fully subscribed

* The preliminary result of Getinge rights issue shows that over 33.7 million shares, corresponding to approximately 99.2 percent of the shares in the offer, were subscribed for with subscription rights

BRIEF-Getinge resolves on fully guaranteed 4 bln SEK rights issue

* says today, the Board of Directors of Getinge AB, with authorization from the Extraordinary General Meeting on August 15, 2017, has resolved on a rights issue of MSEK 4,324 with the purpose to strengthen the group’s balance sheet by reducing leverage and thereby providing...

BRIEF-Getinge to cooperate with Brazilian authorities on cartel probe

* Getinge says to cooperate with Brazilian authorities on local ongoing investigations

UPDATE 1-Getinge Q2 core profit lags forecast, makes new provision over Hechingen

Swedish medical technology firm Getinge posted second-quarter core profits and order intake below expectations on Monday and said it had taken a new provision for quality related work at one of its plants.

RPT-BRIEF-Getinge Q2 core profit lags forecast, makes new provision over Hechingen

* Q2 EBITA before acquisition, restructuring and integration costs increased 9.6% to SEK 864 m (788).

BRIEF-Getinge Q2 core profit lags forecast, makes new provision over Hechingen

* Q2 EBITA before acquisition, restructuring and integration costs increased 9.6% to SEK 864 m (788).

BRIEF-Hanza signs agreement with Getinge

* HANZA SIGNS AGREEMENT WITH GETINGE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Getinge says two of its entities investigated by Brazilian authorities

* Says investigation by the Brazilian Administrative Council for Economic Defense comprises two Getinge entities

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up